Sun, Nov 23, 2014, 11:22 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • yassen_gregorivich yassen_gregorivich May 23, 2013 12:41 AM Flag

    AEGR drug 2.5x more effective than Amgen drug

    Robyn Karnauskas at Deutsche Bank issued a note saying that because Amgen’s PCSK9 shot lowered LDL (low density lipoprotein) cholesterol by only 19%, compared to 50% for Juxtapid, that Amgen’s drug would not be competitive with Aegerion’s.

    Further, it wasn’t clear that Amgen’s PCSK9 drug would even work in the patients with the rare genetic disease that Juxtapid treats, called homozygous familial hypercholesterolemia or HoFH . That’s because blocking PCSK9 lowers cholesterol by blocking turning up the LDL cell receptor, which sucks cholesterol out of the blood. HoFH patients have high cholesterol because their LDL receptors don’t work. So it was unclear whether a PCSK9 drug would do anything for HoFH patients.

    So the Amgen drug may not do anything whatsoever for HoFH patients.
    Kynmaro is even less effective and has liver toxicity issues that make it unsafe.

    Game, Set, Match: Juxtapid (lomitapide)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
21.37+0.42(+2.00%)Nov 21 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Hexcel Corp.
NYSEFri, Nov 21, 2014 4:02 PM EST
XOMA Corporation
NasdaqGMFri, Nov 21, 2014 4:00 PM EST
Exa Corporation
NasdaqGMFri, Nov 21, 2014 3:59 PM EST